Astaxanthin counteracts excitotoxicity and reduces the ensuing increases in calcium levels and mitochondrial reactive oxygen species generation
Artículo
![Thumbnail](/themes/Mirage2/images/cubierta.jpg)
Open/ Download
Access note
Acceso Abierto
Publication date
2020Metadata
Show full item record
Cómo citar
García, Francisca
Cómo citar
Astaxanthin counteracts excitotoxicity and reduces the ensuing increases in calcium levels and mitochondrial reactive oxygen species generation
Author
Abstract
Astaxanthin (ASX) is a carotenoid pigment with strong antioxidant properties. We have reported previously that ASX protects neurons from the noxious effects of amyloid-beta peptide oligomers, which promote excessive mitochondrial reactive oxygen species (mROS) production and induce a sustained increase in cytoplasmic Ca(2+)concentration. These properties make ASX a promising therapeutic agent against pathological conditions that entail oxidative and Ca(2+)dysregulation. Here, we studied whether ASX protects neurons from N-methyl-D-aspartate (NMDA)-induced excitotoxicity, a noxious process which decreases cellular viability, alters gene expression and promotes excessive mROS production. Incubation of the neuronal cell line SH-SY5Y with NMDA decreased cellular viability and increased mitochondrial superoxide production; pre-incubation with ASX prevented these effects. Additionally, incubation of SH-SY5Y cells with ASX effectively reduced the basal mROS production and prevented hydrogen peroxide-induced cell death. In primary hippocampal neurons, transfected with a genetically encoded cytoplasmic Ca(2+)sensor, ASX also prevented the increase in intracellular Ca(2+)concentration induced by NMDA. We suggest that, by preventing the noxious mROS and Ca(2+)increases that occur under excitotoxic conditions, ASX could be useful as a therapeutic agent in neurodegenerative pathologies that involve alterations in Ca(2+)homeostasis and ROS generation.
Patrocinador
CORFO
13IDL2-18271
Comisión Nacional de Investigación Científica y Tecnológica (CONICYT)
CONICYT FONDECYT
11140580
1150736
1170053
1201899
P-09-015
ANID/PIA/ACT192144
BNI
P-09-015
FONDAP
15130011
UBO/VVCM
1905
Indexation
Artículo de publicación ISI Artículo de publicación SCOPUS
Quote Item
Mar. Drugs 2020, 18, 335
Collections
The following license files are associated with this item: